Sunflower Pharmaceutical Group (002737.SZ): Hydrochloride Fexofenadine Oral Suspension Obtains Drug Registration Certificate

Sunflower Pharmaceutical Group (002737.SZ) announced that its subsidiary recently received a drug registration certificate for the registration of oral suspension of fexofenadine hydrochloride issued by the National Medical Products Administration. The oral suspension of fexofenadine hydrochloride is used in the anti-allergy field. The approval of this product will help the company expand its product line, improve its product category layout, and enhance its coverage in the field of treatment. The company will accelerate the subsequent mass production and listing of the product to achieve rapid transformation of research and development achievements.